Toxemia: Clinical Trials

10 trials for Toxemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 110Completed 10

Follow Toxemia: new trials by email Literature Review of Toxemia trials Research Report on Toxemia

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS
Allocetra-OTS - Organ Dysfunction Syndrome Sepsis
Phase 1CompletedEnlivex Therapeutics Ltd.102019-01-272020-05-19
PK/PD of EA-230 During Endotoxemia
EA-230, Endotoxin, Placebo - Endotoxemia, Systemic Inflammatory Response
Phase 1CompletedRadboud University Medical Center602015-02-012016-06-23
Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections
CAZ-AVI - Systemic Infections
Phase 1CompletedPfizer352013-07-012017-09-06
Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)
Antibiotic - Systemic Infection
Phase 1CompletedPhillip Brian Smith632013-01-012023-07-27
A Possible Therapeutic Role for Adenosine During Inflammation
AMPD1 polymorphism, Caffeine infusion, placebo - Endotoxemia
Phase 1CompletedRadboud University Medical Center332007-08-012009-10-01
Anti-Inflammatory Effect of Statins in the Human Endotoxin Model
LPS 2ng/kg intravenous bolus, Simvastatin 80mg; administered daily p.o. over 5 days, Rosuvastatin 40mg; administered daily p.o. over 5 days - Endotoxemia
Phase 1CompletedMedical University of Vienna62006-03-012007-01-05
Ethnic Differences in the Inflammatory Response in Systemic Inflammation
LPS - Endotoxemia
Phase 1CompletedMedical University of Vienna322006-01-012006-09-13
Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans
repeated injections of endotoxin during 5 days - Endotoxemia
Phase 1CompletedRadboud University Medical Center162005-10-012008-04-15
Effect of Selective iNOS Inhibition During Human Endotoxemia
Aminoguanidine, endotoxin - Endotoxemia
Phase 1CompletedRadboud University Medical Center72005-01-012008-04-15
Blockade of Vascular Potassium Channels During Human Endotoxemia
endotoxin, Potassium channel blockers: TEA, Quinin, Tolbutamide, L-NMMA - Endotoxemia
Phase 1CompletedRadboud University Medical Center362003-01-012008-10-17

Narrower conditions

Endotoxemia (7)  ·  Inflammation (1)

Broader conditions

Infections (10)  ·  Bacteremia (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Sepsis (7)  ·  Systemic Inflammatory Response Syndrome (7)  ·  Inflammation (6)

Interventions

Endotoxins (3)  ·  Lipopolysaccharides (2)  ·  Anti-Bacterial Agents (1)  ·  Tolbutamide (1)  ·  alanyl-glutaminyl-glycyl-valine (1)  ·  omega-N-Methylarginine (1)  ·  pimagedine (1)

Sponsors

Radboud University Medical Center (5)  ·  Medical University of Vienna (2)  ·  Enlivex Therapeutics Ltd. (1)  ·  Pfizer (1)  ·  Phillip Brian Smith (1)

Countries

Netherlands (4)  ·  Austria (2)  ·  United States (2)  ·  Israel (1)

Top investigators

Christa Firbas, MD (1)  ·  Dror Mevorach, Prof (1)  ·  John Bradley, MD (1)  ·  Michael Wolzt, MD (1)  ·  P Pickkers, MD, Prof. (1)  ·  Paul Newell, MBBS, MRCP (1)  ·  Peter Pickkers, MD PhD (1)  ·  Peter Pickkers, MD, PhD (1)  ·  Peter Pickkers, MD,PhD (1)  ·  Peter Pickkers, PhD (1)  ·  Philip B Smith, MD (1)

Results publications

PMID 16864730, PMID 18433844, PMID 20444270, PMID 21211004, PMID 26926644, PMID 27503642, PMID 28137820, PMID 30710387, PMID 30910891, PMID 30919998, PMID 34659208, PMID 34687548